Abstract
Tumor-initiating cells (TICs) are particularly efficient at evading detection and elimination by the human immune system. Recent data from Yang and collaborators demonstrate that – at least in preclinical hepatocellular carcinoma models – the immunological privilege of CD49f+ TICs can be limited by targeting CD155, resulting in restored sensitivity to immune checkpoint inhibitors.
| Original language | English |
|---|---|
| Pages (from-to) | 4-6 |
| Number of pages | 3 |
| Journal | Trends in Immunology |
| Volume | 46 |
| Issue number | 1 |
| Early online date | Nov 24 2024 |
| DOIs | |
| State | Published - Jan 2025 |
Keywords
- CCL4
- myeloid-derived suppressor cells
- neutrophils
- NK cells
- PD-1
- TIGIT
- Tumor Escape
- Immune Checkpoint Inhibitors/pharmacology
- Humans
- Neoplastic Stem Cells/immunology
- Carcinoma, Hepatocellular/immunology
- Animals
- Immune Evasion
- Liver Neoplasms/immunology